Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cash flow from operations refers to the cash brought in through a company's normal business operations. It is the cash flow before any investment or financing activities. It is the cash version of net income.
Hisamitsu Pharmaceutical Co (FSE:4530) Cash Flow from Operations Explanation
For companies reported in indirect method, cash flow from operations contains six items:
1. Net Income From Continuing Operations:
Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.
Hisamitsu Pharmaceutical Co's net income from continuing operations for the
three
months ended in Nov. 2025 was 円4,989 Mil.
2. Depreciation, Depletion and Amortization:
Depreciation is a present expense that accounts for the past cost of an asset that is now providing benefits.
Depletion and amortization are synonyms for depreciation.
Generally:
The term depreciation is used when discussing man made tangible assets
The term depletion is used when discussing natural tangible assets
The term amortization is used when discussing intangible assets
Hisamitsu Pharmaceutical Co's depreciation, depletion and amortization for the
three
months ended in Nov. 2025 was 円0 Mil.
3. Change In Working Capital:
Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities. Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow.
Hisamitsu Pharmaceutical Co's change in working capital for the
three
months ended in Nov. 2025 was 円0 Mil. It means Hisamitsu Pharmaceutical Co's working capital
{id_Q12}
from Aug. 2025 to Nov. 2025 .
4. Deferred Tax:
It is the cash flow generated from deferred tax.
Hisamitsu Pharmaceutical Co's cash flow from deferred tax for the
three
months ended in Nov. 2025 was 円0 Mil.
Hisamitsu Pharmaceutical Co's cash from discontinued operating Activities for the
three
months ended in Nov. 2025 was 円0 Mil.
6. Asset Impairment Charge:
It is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.
Hisamitsu Pharmaceutical Co's asset impairment charge for the
three
months ended in Nov. 2025 was 円0 Mil.
7. Stock Based Compensation:
It is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.
Hisamitsu Pharmaceutical Co's stock based compensation for the
three
months ended in Nov. 2025 was 円0 Mil.
8. Cash Flow from Others:
These are cash differences caused by the change of inventory, accounts payable, accounts receivable etc. For instance, if a company pays its suppliers slower, its cash position will build up faster. If a company receives payments from its customers slower, its account receivables will rise, and its cash position will grow more slowly (or even shrink).
Hisamitsu Pharmaceutical Co's cash flow from others for the
three
months ended in Nov. 2025 was 円0 Mil.
Hisamitsu Pharmaceutical Co Cash Flow from Operations Related Terms
Hisamitsu Pharmaceutical Co Cash Flow from Operations Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hisamitsu Pharmaceutical Co Cash Flow from Operations Chart
Hisamitsu Pharmaceutical Co Cash Flow from Operations Calculation
Cash flow from operations refers to the cash brought in through a company's normal business operations. It is the cash flow before any investment or financing activities. It is the cash version of net income.
Hisamitsu Pharmaceutical Co's Cash Flow from Operations for the fiscal year that ended in Feb. 2026 is calculated as:
Cash Flow from Operations for the trailing twelve months (TTM) ended in Nov. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was 円0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Cash Flow from Operations of 円0 Mil mean?
Hisamitsu Pharmaceutical Co (FSE:4530) has a Cash Flow from Operations of 円0 Mil as of Nov. 2025. Cash Flow from Operations is the amount of cash earned or paid from standard business operations. View historical data for Hisamitsu Pharmaceutical Co and its competitors.
Is Hisamitsu Pharmaceutical Co's Cash Flow from Operations too high?
Hisamitsu Pharmaceutical Co's current Cash Flow from Operations is 円0 Mil. Overall, Hisamitsu Pharmaceutical Co has a GF Score™ of 89/100, reflecting its overall financial health beyond just this single metric.
How does Hisamitsu Pharmaceutical Co's Cash Flow from Operations compare to AMPH and ESPR?
Hisamitsu Pharmaceutical Co's Cash Flow from Operations of 円0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow from Operations for a Drug Manufacturers company?
A good Cash Flow from Operations depends on the Drug Manufacturers industry context. However, Cash Flow from Operations should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow from Operations mean?
A high Cash Flow from Operations can signal that a stock is expensive relative to its fundamentals. Cash Flow from Operations is the amount of cash earned or paid from standard business operations. View historical data for Hisamitsu Pharmaceutical Co and its competitors. Hisamitsu Pharmaceutical Co's current Cash Flow from Operations is 円0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hisamitsu Pharmaceutical Co stock overvalued right now?
Hisamitsu Pharmaceutical Co (FSE:4530) has a current Cash Flow from Operations of 円0 Mil. The stock's GF Value™ is 円3,237.07, compared to a current price of 円3,975.00 — trading 22.8% above its estimated fair value. The current Cash Flow from Operations is 円0 Mil. Hisamitsu Pharmaceutical Co's overall GF Score™ is 89/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow from Operations calculated?
Cash Flow from Operations is calculated from a company's financial statements. For Hisamitsu Pharmaceutical Co (FSE:4530), the current Cash Flow from Operations is 円0 Mil as of Nov. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hisamitsu Pharmaceutical Co (FSE:4530) Overvalued in 2026?
Based on GuruFocus' analysis, Hisamitsu Pharmaceutical Co stock appears to be overvalued.
The current stock price of 円3,975.00 is trading 22.8% above its estimated GF Value™ of 円3,237.07.
Key valuation signals for FSE:4530:
Cash Flow from Operations: 円0 Mil
GF Value™: 円3,237.07 vs. price of 円3,975.00 (22.8% above fair value)
No single metric tells the full story. See the FSE:4530 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hisamitsu Pharmaceutical Co Inc is engaged in the research, development, manufacturing, procurement, and sale of pharmaceutical products. The company operates a single business segment, focusing on medical and general pharmaceuticals both in Japan and overseas. It markets drugs under the Salonpas, Nobinobi / Salonsip, Butenalock, and Mohrus brands, which mainly serve topical medication needs with pain relief creams, gels, sprays, lotions, and ointments.
89GF Score
Get the complete analysis for FSE:4530
Cash Flow from Operations is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FSE:4530 has been successfully added to your 
